{"id":12047,"date":"2017-04-20T20:32:36","date_gmt":"2017-04-20T19:32:36","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=12047"},"modified":"2017-04-21T09:27:59","modified_gmt":"2017-04-21T08:27:59","slug":"fase-iib-studie-pa-en-ny-tb-vaksine","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2017\/04\/20\/fase-iib-studie-pa-en-ny-tb-vaksine\/","title":{"rendered":"[:no]Fase IIb studie p\u00e5 en ny TB vaksine[:en]Phase IIb trial of a novel TB vaccine[:]"},"content":{"rendered":"<p>[:no]Vaksinen representerer et paradigmeskifte i det den er den f\u00f8rst pre-eksponeringsvaksine for \u00e5 forhindre tuberkul\u00f8s infeksjon. Prosjektet ble nylig l\u00f8ftet fram av EU (EDCTP) p\u00e5 verdens tuberkulosedag. Det finansiert av GLOBVAC og prosjektet koordineres fra K2 av Harleen Grewal. Det er all grunn til \u00e5 gratulere, Harleen!<\/p>\n<p><a href=\"http:\/\/www.edctp.org\/news\/world-tb-day-2017-closing-gaps-end-tuberculosis\/\">http:\/\/www.edctp.org\/news\/world-tb-day-2017-closing-gaps-end-tuberculosis\/<\/a>[:en]This vaccine represents a paradigm shift in the fact that this is the first pre-exposure vaccine to target prevention of TB infection. The project was recently showcased by EU (EDCTP) on the World TB day. It is funded by RCN-GLOBVAC and the project is coordinated from K2 by Harleen Grewal. It is every reason to congratulate, Harleen!<\/p>\n<p><a href=\"http:\/\/www.edctp.org\/news\/world-tb-day-2017-closing-gaps-end-tuberculosis\/\">http:\/\/www.edctp.org\/news\/world-tb-day-2017-closing-gaps-end-tuberculosis\/<\/a>[:]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[:no]Vaksinen representerer et paradigmeskifte i det den er den f\u00f8rst pre-eksponeringsvaksine for \u00e5 forhindre tuberkul\u00f8s infeksjon. Prosjektet ble nylig l\u00f8ftet fram av EU (EDCTP) p\u00e5 verdens tuberkulosedag. Det finansiert av GLOBVAC og prosjektet koordineres fra K2 av Harleen Grewal. Det&hellip;<\/p>\n<p class=\"more-link-p\"><a class=\"more-link\" href=\"https:\/\/k2info.w.uib.no\/en\/2017\/04\/20\/fase-iib-studie-pa-en-ny-tb-vaksine\/\">Read more &rarr;<\/a><\/p>\n","protected":false},"author":3699,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-12047","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/3699"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=12047"}],"version-history":[{"count":1,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12047\/revisions"}],"predecessor-version":[{"id":12048,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12047\/revisions\/12048"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=12047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=12047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=12047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}